BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29030718)

  • 1. Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study.
    Rudà R; Pellerino A; Franchino F; Bertolotti C; Bruno F; Mo F; Migliore E; Ciccone G; Soffietti R
    J Neurooncol; 2018 Jan; 136(1):105-114. PubMed ID: 29030718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.
    Zadeh WW; Escartin A; Byrnes W; Tennigkeit F; Borghs S; Li T; Dedeken P; De Backer M;
    Seizure; 2015 Sep; 31():72-9. PubMed ID: 26362380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
    Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
    Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
    Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
    Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES).
    Rudà R; Houillier C; Maschio M; Reijneveld JC; Hellot S; De Backer M; Chan J; Joeres L; Leunikava I; Glas M; Grant R
    Epilepsia; 2020 Apr; 61(4):647-656. PubMed ID: 32329527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early add-on lacosamide in a real-life setting: results of the REALLY study.
    Villanueva V; Garcés M; López-Gomáriz E; Serratosa JM; González-Giráldez B; Parra J; Rodríguez-Uranga J; Toledo M; López González FJ; Bermejo P; Giner P; Castillo A; Molins A; Campos D; Mauri JÁ; Muñoz R; Bonet M; Serrano-Castro P; del Villar A; Saiz-Díaz RA;
    Clin Drug Investig; 2015 Feb; 35(2):121-31. PubMed ID: 25488477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
    Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
    Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenges of assessing effectiveness of lacosamide using electronic medical record databases.
    Kalilani L; Halpern R; Seare J; Dedeken P
    Epilepsy Behav; 2018 Aug; 85():195-199. PubMed ID: 30032807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures.
    Steinhoff BJ; Eckhardt K; Doty P; De Backer M; Brunnert M; Schulze-Bonhage A
    Epilepsy Behav; 2016 May; 58():35-43. PubMed ID: 27054272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension.
    Wechsler RT; Yates SL; Messenheimer J; Leroy R; Beller C; Doty P
    Epilepsy Res; 2017 Feb; 130():13-20. PubMed ID: 28086164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy.
    Villanueva V; Saiz-Diaz R; Toledo M; Piera A; Mauri JA; Rodriguez-Uranga JJ; López-González FJ; Gómez-Ibáñez A; Garcés M; González de la Aleja J; Rodríguez-Osorio X; Palao-Duarte S; Castillo A; Bonet M; Ruiz-Giménez J; Palau J; Arcediano A; Toledo M; Gago A
    Epilepsy Behav; 2016 Dec; 65():25-32. PubMed ID: 27863278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.
    Rudà R; Bello L; Duffau H; Soffietti R
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv55-64. PubMed ID: 23095831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting.
    Sanmartí-Vilaplana F; Díaz-Gómez A
    Epilepsy Behav; 2018 Feb; 79():130-137. PubMed ID: 29287216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lacosamide on background eeg activity in brain tumor-related epilepsy patients: A case series study.
    Maschio M; Zarabla A; Maialetti A; Sperati F; Dinapoli L; Dispenza S; Petreri G; Cantelmi T
    Brain Behav; 2018 Nov; 8(11):e01067. PubMed ID: 30334378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
    Mo F; Meletti S; Belcastro V; Quadri S; Napolitano M; Bello L; Dainese F; Scarpelli M; Florindo I; Mascia A; Pauletto G; Bruno F; Pellerino A; Giovannini G; Polosa M; Sessa M; Conti Nibali M; Di Gennaro G; Gigli GL; Pisanello A; Cavallieri F; Rudà R
    J Neurooncol; 2022 May; 157(3):551-559. PubMed ID: 35397759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region.
    Arabi M; Alsaadi T; Nasreddine W; Al-Hashel J; Dirani M; Beydoun A
    Epilepsy Behav; 2018 Jul; 84():118-121. PubMed ID: 29778846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
    Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
    Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparison of efficacy of levetiracetam and lacosamide add-on treatments in patients with partial onset seizure.
    Acar T; Aras YG
    Ideggyogy Sz; 2018 May; 71(5-06):197-204. PubMed ID: 29889462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.